
Phase 3 biotech developing stem cell therapies for hematologic malignancies.
Industry: Health Care
First Day Return: +5.5%

| IPO Date | 10/26/2018 |
|---|---|
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| IPO Intelligence Only |
| Headquarters | Jerusalem, Israel |
|---|---|
| Founded | 1998 |
| Employees at IPO | 52 |
| Website www.gamida-cell.com | |